{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:00:10Z","timestamp":1791453610648,"version":"4.3.3"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.parkreldis.2023.105385","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T04:36:07Z","timestamp":1680064567000},"page":"105385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?"],"prefix":"10.1016","volume":"112","author":[{"given":"Ece","family":"Bayram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-2803","authenticated-orcid":false,"given":"Lucia","family":"Batzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bension","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Jagota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Biundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tittaya","family":"Prasertpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lazcano-Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimona S.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2023.105385_bib1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2023.105385_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson's disease: a community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2023.105385_bib3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","article-title":"The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort","volume":"84","author":"Williams-Gray","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2023.105385_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/0891988712464823","article-title":"Cognitive impairment in Parkinson disease","volume":"25","author":"Leroi","year":"2012","journal-title":"J. Geriatr. Psychiatr. Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1212\/WNL.0000000000003634","article-title":"Natural course of mild cognitive impairment in Parkinson disease","volume":"88","author":"Pedersen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2023.105385_bib8","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2023.105385_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological management of Lewy body dementia: a systematic review and meta-analysis","volume":"172","author":"Stinton","year":"2015","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2023.105385_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2023.105385_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/gps.4109","article-title":"Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies","volume":"30","author":"Wesnes","year":"2015","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2023.105385_bib15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2023.105385_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329136","article-title":"Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis","author":"David","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2023.105385_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.22307","article-title":"Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study","volume":"24","author":"Marsh","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mdc3.12455","article-title":"A randomized clinical trial of atomoxetine for mild cognitive impairment in Parkinson's disease","volume":"4","author":"Hinson","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2023.105385_bib19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/mds.25866","article-title":"The spectrum of cognitive impairment in Lewy body diseases","volume":"29","author":"Goldman","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","article-title":"Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies","volume":"125","author":"Jellinger","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2023.105385_bib21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2023.105385_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000094","article-title":"The GRADE system for rating clinical guidelines","volume":"6","author":"Kavanagh","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.parkreldis.2023.105385_bib23","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/mds.28582","article-title":"Allogeneic bone marrow\u2013derived mesenchymal stem cell safety in idiopathic Parkinson's disease","volume":"36","author":"Schiess","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2023.105385_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/mds.28879","article-title":"Safety and efficacy of mevidalen in Lewy body dementia: a Phase 2, randomized, placebo-controlled trial","volume":"37","author":"Biglan","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib26","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/mds.28198","article-title":"Safety of plasma infusions in Parkinson's disease","volume":"35","author":"Parker","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.26102","article-title":"\u03b14\u03b22 * nicotinic cholinergic receptor target engagement in Parkinson disease gait\u2013balance disorders","volume":"90","author":"Albin","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib28","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.25864","article-title":"Non\u2010motor symptoms in Parkinson's disease are reduced by nabilone","volume":"88","author":"Peball","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib29","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/biomedicines9121881","article-title":"Low-dose niacin supplementation improves motor function in US veterans with Parkinson's disease: a single-center, randomized, placebo-controlled trial","volume":"9","author":"Wakade","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.parkreldis.2023.105385_bib30","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/mds.28630","article-title":"Expectations of benefit in a trial of a candidate disease\u2010modifying treatment for Parkinson disease","volume":"36","author":"Mestre","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2022.863930","article-title":"Immersive technology for cognitive-motor training in Parkinson's disease","volume":"16","author":"Lau","year":"2022","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.parkreldis.2023.105385_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263108","article-title":"Goal management training and psychoeducation\/mindfulness for treatment of executive dysfunction in Parkinson's disease: a feasibility pilot trial","volume":"17","author":"Gigu\u00e8re-Rancourt","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2023.105385_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.parkreldis.2021.01.013","article-title":"Art therapy for Parkinson's disease","volume":"84","author":"Cucca","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib34","article-title":"Computerized physical exercise improves the functional architecture of the brain in patients with Parkinson's Disease: a network science resting-state EEG study","author":"Xefteris","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.parkreldis.2023.105385_bib35","article-title":"Can Qigong improve non-motor symptoms in people with Parkinson's disease - a pilot randomized controlled trial?","volume":"39","author":"Moon","year":"2020","journal-title":"Compl. Ther. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2023.105385_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1021","article-title":"Implementation of the HiBalance training program for Parkinson's disease in clinical settings: a feasibility study","volume":"8","author":"Joseph","year":"2018","journal-title":"Brain Behav."},{"key":"10.1016\/j.parkreldis.2023.105385_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12883-021-02101-2","article-title":"Physical activity profiles in Parkinson's disease","volume":"21","author":"von Rosen","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2053","article-title":"Implementation of high\u2010cadence cycling for Parkinson's disease in the community setting: a pragmatic feasibility study","volume":"11","author":"McKee","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.parkreldis.2023.105385_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/0269215520907669","article-title":"Group-based music intervention in Parkinson's disease \u2013 findings from a mixed-methods study","volume":"34","author":"Pohl","year":"2020","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.parkreldis.2023.105385_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.parkreldis.2022.02.018","article-title":"Effect of eight-week online cognitive training in Parkinson's disease: a double-blind, randomized, controlled trial","volume":"96","author":"van Balkom","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1159\/000520591","article-title":"Effects of computer-based cognitive rehabilitation on attention, executive functions, and quality of life in patients with Parkinson's disease: a randomized, controlled, single-blinded pilot study","volume":"50","author":"Svaerke","year":"2021","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"10.1016\/j.parkreldis.2023.105385_bib42","first-page":"55","article-title":"The effect of repetitive transcranial magnetic stimulation on cognitive impairment in Parkinson's disease with dementia: pilot study","volume":"38","author":"Khedr","year":"2020","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.parkreldis.2023.105385_bib43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.parkreldis.2019.05.031","article-title":"Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease","volume":"65","author":"Wilkinson","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib44","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1038\/s41598-022-12061-3","article-title":"Clinical evaluation and resting state fMRI analysis of virtual reality based training in Parkinson's disease through a randomized controlled trial","volume":"12","author":"Hajebrahimi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2023.105385_bib45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brs.2020.12.014","article-title":"Cognitive effects of theta frequency bilateral subthalamic nucleus stimulation in Parkinson's disease: a pilot study","volume":"14","author":"Lam","year":"2021","journal-title":"Brain Stimul."},{"key":"10.1016\/j.parkreldis.2023.105385_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.584374","article-title":"Theta-burst stimulation for cognitive enhancement in Parkinson's disease with mild cognitive impairment: a randomized, double-blind, sham-controlled trial","volume":"11","author":"Lang","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mds.27863","article-title":"Short versus conventional pulse\u2010width deep brain stimulation in Parkinson's disease: a randomized crossover comparison","volume":"35","author":"Dayal","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib48","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/mds.28953","article-title":"Lateralized subthalamic stimulation for axial dysfunction in Parkinson's disease: a randomized trial","volume":"37","author":"Liz\u00e1rraga","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib49","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-179901","article-title":"Clinical trials for disease-modifying therapies in Alzheimer's disease: a primer, lessons learned, and a blueprint for the future","volume":"64","author":"Cummings","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.parkreldis.2023.105385_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2023.105385_bib51","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2023.105385_bib52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JPD-213113","article-title":"Does ethnicity influence recruitment into clinical trials of Parkinson's disease?","volume":"12","author":"Lau","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2023.105385_bib53","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66546","article-title":"Open science takes on Parkinson's disease","volume":"10","author":"Riley","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.parkreldis.2023.105385_bib54","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/mds.28921","article-title":"Unmet needs of women living with Parkinson's disease: gaps and controversies","volume":"37","author":"Subramanian","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib55","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.parkreldis.2021.05.019","article-title":"Expanding sexual and gender minority research in movement disorders: more than awareness and acceptance","volume":"87","author":"Roy Lin","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"10.1016\/j.parkreldis.2023.105385_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h3029","article-title":"Dementia: timely diagnosis and early intervention","volume":"350","author":"Robinson","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2023.105385_bib58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12264-019-00429-x","article-title":"Early intervention in Alzheimer's disease: how early is early enough?","volume":"36","author":"Fan","year":"2020","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.parkreldis.2023.105385_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib60","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(17)30122-9","article-title":"Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts","volume":"16","author":"Liu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib61","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.0000000000002437","article-title":"Development and external validation of a prognostic model in newly diagnosed Parkinson disease","volume":"86","author":"Velseboer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2023.105385_bib62","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0000000000000842","article-title":"Predictors of dementia in Parkinson disease: a prospective cohort study","volume":"83","author":"Anang","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2023.105385_bib63","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/mds.28477","article-title":"Visual dysfunction predicts cognitive impairment and white matter degeneration in Parkinson's disease","volume":"36","author":"Zarkali","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib64","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/mds.28182","article-title":"Visual impairment is more common in Parkinson's disease and is a risk factor for poor Health outcomes","volume":"35","author":"Hamedani","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib65","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/mds.28184","article-title":"Visual acuity and development of Parkinson's disease: a nationwide cohort study","volume":"35","author":"Han","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib66","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/arclin\/acx092","article-title":"Cognitive rehabilitation in Parkinson's disease: is it feasible?","volume":"32","author":"Biundo","year":"2017","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib67","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1191\/1740774505cn125oa","article-title":"Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials","volume":"2","author":"Guimaraes","year":"2005","journal-title":"Clin. Trials"},{"key":"10.1016\/j.parkreldis.2023.105385_bib68","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3233\/JAD-161109","article-title":"Long-term cognitive decline in dementia with Lewy bodies in a large multicenter, international cohort","volume":"57","author":"Kramberger","year":"2017","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.parkreldis.2023.105385_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-662-44519-8_8","article-title":"Great expectations: the placebo effect in Parkinson's disease","author":"Lidstone","year":"2014","journal-title":"Placebo"},{"key":"10.1016\/j.parkreldis.2023.105385_bib70","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/08039488.2018.1468480","article-title":"The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study","volume":"72","author":"Morberg","year":"2018","journal-title":"Nord. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2023.105385_bib71","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S1474-4422(16)00066-1","article-title":"Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects","volume":"15","author":"Benedetti","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1123\/jab.2013-0319","article-title":"Spatiotemporal gait patterns during overt and covert evaluation in patients with Parkinson's disease and healthy subjects: is there a Hawthorne effect?","volume":"31","author":"Robles-Garc\u00eda","year":"2015","journal-title":"J. Appl. Biomech."},{"key":"10.1016\/j.parkreldis.2023.105385_bib73","first-page":"21","article-title":"Impact of Hawthorne effect on healthcare professionals: a systematic review","volume":"96","author":"Choi","year":"2019","journal-title":"Univ. Toronto Med. J."},{"key":"10.1016\/j.parkreldis.2023.105385_bib74","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.parkreldis.2023.105385_bib75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.parkreldis.2023.105385_bib76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00702-016-1517-6","article-title":"MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study","volume":"123","author":"Biundo","year":"2016","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2023.105385_bib77","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000496454","article-title":"Responsiveness to change of the montreal cognitive assessment, mini-mental state examination, and SCOPA-cog in non-demented patients with Parkinson's disease","volume":"47","author":"Faust-Socher","year":"2019","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"10.1016\/j.parkreldis.2023.105385_bib78","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/mds.110","article-title":"Detecting mild cognitive deficits in Parkinson's disease: comparison of neuropsychological tests","volume":"33","author":"Hoogland","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2023.105385_bib79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-022-00299-w","article-title":"Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations","volume":"11","author":"Rodriguez-Porcel","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.parkreldis.2023.105385_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.conb.2019.11.019","article-title":"An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead","volume":"61","author":"Simr\u00e9n","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.parkreldis.2023.105385_bib81","first-page":"2545","article-title":"Can neuroimaging predict dementia in Parkinson's disease?","volume":"141","author":"Lanskey","year":"2018","journal-title":"Brain"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802023001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802023001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:29:01Z","timestamp":1761179341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802023001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":81,"alternative-id":["S1353802023001086"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105385","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105385"}}